437
Views
21
CrossRef citations to date
0
Altmetric
Review

Neurokinin receptor antagonism: a patent review (2014-present)

&
Pages 527-539 | Received 31 Jan 2020, Accepted 12 May 2020, Published online: 27 May 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Slobodan M. Janković & Miralem Đešević. (2022) Advancements in neuroactive peptides in seizures. Expert Review of Neurotherapeutics 22:2, pages 129-143.
Read now

Articles from other publishers (20)

Santiago Michavila Puente-Villegas, Luis Apaza Ticona, Ángel Rumbero Sánchez & José-Luis Acebes. (2024) Diterpenes of Pinus pinaster aiton with anti-inflammatory, analgesic, and antibacterial activities. Journal of Ethnopharmacology 318, pages 117021.
Crossref
Juliane Becker, Philip R. Effraim, Sulayman Dib-Hajj & Heike L. Rittner. (2023) Lessons learned in translating pain knowledge into practice. PAIN Reports 8:6, pages e1100.
Crossref
Katarzyna Witoszka, Joanna Matalińska, Aleksandra Misicka & Piotr F. J. Lipiński. (2023) Moving out of CF 3 ‐Land: Synthesis, Receptor Affinity, and in silico Studies of NK1 Receptor Ligands Containing a Pentafluorosulfanyl (SF 5 ) Group . ChemMedChem 18:23.
Crossref
Arash Soltani & Seyed Isaac Hashemy. (2023) Homology modeling, virtual screening, molecular docking, and ADME approaches to identify a potent agent targeting NK2R protein. Biotechnology and Applied Biochemistry.
Crossref
Fatima Hassan, Anam Saleem, Sehar Saba Samuel, Zouina Sarfraz, Azza Sarfraz, Muzna Sarfraz & Manish KC. (2023) Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy. Medicine 102:23, pages e33978.
Crossref
Somayeh Kouhetsani, Homayoun Khazali & Hassan Rajabi-Maham. (2023) Orexin antagonism and substance-P: Effects and interactions on polycystic ovary syndrome in the wistar rats. Journal of Ovarian Research 16:1.
Crossref
Safieh Ebrahimi, Bahareh Erfani, Abbas Alalikhan, Hamidreza Ghorbani, Mahdi Farzadnia, Amir R. Afshari, BaratAli Mashkani & Seyed Isaac Hashemy. (2023) The In Vitro Pro-inflammatory Functions of the SP/NK1R System in Prostate Cancer: a Focus on Nuclear Factor-Kappa B (NF-κB) and Its Pro-inflammatory Target Genes. Applied Biochemistry and Biotechnology.
Crossref
Manuel Lisardo Sánchez, Francisco D. Rodríguez & Rafael Coveñas. (2023) Peptidergic Systems and Cancer: Focus on Tachykinin and Calcitonin/Calcitonin Gene-Related Peptide Families. Cancers 15:6, pages 1694.
Crossref
Wenjing Sun, Qingning Yuan, Huanhuan Zhang, Fan Yang, Shenglong Ling, Yifan Luo, Pei Lv, H. Eric Xu, Changlin Tian, Wanchao Yin & Pan Shi. (2022) Structural insights into the activation of neurokinin 2 receptor by neurokinin A. Cell Discovery 8:1.
Crossref
Rafael Coveñas, Francisco D. Rodríguez & Miguel Muñoz. (2022) The Neurokinin-1 Receptor: A Promising Antitumor Target. Receptors 1:1, pages 72-97.
Crossref
Mohammed Ali Alsaeed, Safieh Ebrahimi, Abbas Alalikhan, Seyedeh Fatemeh Hashemi & Seyed Isaac Hashemy. (2022) The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis. BioMed Research International 2022, pages 1-9.
Crossref
Rafael Coveñas & Miguel Muñoz. (2022) Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer. Cancers 14:14, pages 3539.
Crossref
Joanna Matalińska & Piotr F.J. Lipiński. (2022) Correcting a widespread error: Neuroprotectant N-acetyl-L-tryptophan does not bind to the neurokinin-1 receptor. Molecular and Cellular Neuroscience 120, pages 103728.
Crossref
Safieh Ebrahimi, Abbas Alalikhan, Seyed Hamid Aghaee-Bakhtiari & Seyed Isaac Hashemy. (2022) The redox modulatory effects of SP/NK1R system: Implications for oxidative stress-associated disorders. Life Sciences 296, pages 120448.
Crossref
C.M. Schooling. (2022) Genetic validation of neurokinin 3 receptor antagonists for ischemic heart disease prevention in men – A one-sample Mendelian randomization study. eBioMedicine 77, pages 103901.
Crossref
YuanLin Sun, Bin Liu, YuJia Chen, YanPeng Xing & Yang Zhang. (2022) Multi-Omics Prognostic Signatures Based on Lipid Metabolism for Colorectal Cancer. Frontiers in Cell and Developmental Biology 9.
Crossref
Mahtab Mozafari, Safieh Ebrahimi, Reza Assaran Darban & Seyed Isaac Hashemy. (2021) Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer. Molecular Biology Reports 49:2, pages 1067-1076.
Crossref
Francisco Esteban, Pablo Ramos-García, Miguel Muñoz & Miguel Ángel González-Moles. (2021) Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature. International Journal of Environmental Research and Public Health 19:1, pages 375.
Crossref
Yue Shi, Xi Wang, Yueming Meng, Junjie Ma, Qiyu Zhang, Gang Shao, Lingfei Wang, Xurui Cheng, Xiangyu Hong, Yong Wang, Zhibin Yan, Yihai Cao, Jian Kang & Caiyun Fu. (2021) A Novel Mechanism of Endoplasmic Reticulum Stress‐ and c‐Myc‐Degradation‐Mediated Therapeutic Benefits of Antineurokinin‐1 Receptor Drugs in Colorectal Cancer. Advanced Science 8:21, pages 2101936.
Crossref
Miguel Ángel González-Moles, Pablo Ramos-García & Francisco Esteban. (2021) Significance of the Overexpression of Substance P and Its Receptor NK-1R in Head and Neck Carcinogenesis: A Systematic Review and Meta-Analysis. Cancers 13:6, pages 1349.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.